While Bluebird already has two approved gene therapies, investors are focused on lovo-cel as its most promising product. Bluebird is seeking approval of the therapy for patients who are at least 12 years old and have a history of vaso-occlusive events; it estimates that about 20,000 people in the U.S. would be eligible for the treatment.
Even if the company can only win over a relatively small percentage of that group, lovo-cel has the potential to yield sales of $2 billion or more, based on its expected price tag, Baird analyst Jack Allen wrote in a note to clients Wednesday. The company priced its two approved gene therapies at $2.8 million and $3 million per patient.
